Panacea Biotec Shares Jump 9% on DengiALL Phase III Update

Panacea Biotec shares jumped 9.3 per cent on the BSE on Wednesday, touching an intra-day high of ?418.35 per share, after the company announced the completion of enrollment for the Phase III clinical trial of its tetravalent dengue vaccine candidate, DengiALL.

Buying interest in the stock emerged despite weakness in the broader market. The company said it has enrolled 10,335 participants across 19 clinical trial sites in India. These participants will be monitored for two years after dosing with either the vaccine or a placebo to assess efficacy and immunogenicity.

Panacea Biotec expects DengiALL to be India’s first indigenous single-shot dengue vaccine, with a potential market launch by 2027.

“We are now delighted to inform you that enrollment of study participants in the context of DengiAll Phase-III clinical trial has been completed,” the filing read.

DengiALL is designed to protect against all four dengue virus serotypes—DEN-1 to DEN-4—using attenuated virus strains to provide balanced immunity and reduce the risk of severe disease from secondary infections.

The Phase III trial began after approval from the Drugs Controller General of India in August 2024. Development of the vaccine started in 2006 following a technology transfer from the US National Institutes of Health. Phase I/II trials in India were completed with three years of safety follow-up in 2020, and Panacea later entered into an MoU with ICMR in March 2022 for the Phase III study.